In December, when Puma Biotechnology Inc. disclosed data with the breast cancer drug Nerlynx (neratinib), a kinase inhibitor that irreversibly binds to EGFR, HER2 and HER4, questions that were already on the burner bubbled harder regarding the drug's future, especially given the shifting treatment setup in HER2-positive disease.